Trial Profile
A Study to Evaluate the Defective Mismatch Repair (dMMR) Status as a Predictive Biomarker of Efficacy in Chinese Patients With Metastatic Colorectal Cancer (mCRC) Treated With Bevacizumab + Chemotherapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Apr 2016
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Colorectal cancer
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 04 Apr 2016 New trial record